GlassScriptPhysician profile
Davis Brian Berry
NPI 1427541515
$1,340.48
in general payments reported to CMS, 2019-2025
16 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.38 · 2024: $233 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.24 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $546.93 | 2024-2025 | |
| Janssen Biotech, INC. | $211.80 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $126.59 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $76.58 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $66.40 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.31 | 2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $50.34 | 2025 | |
| Gilead Sciences, INC. | $46.90 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.65 | 2024-2025 | Entyvio |
| Lucid Diagnostics INC. | $23.46 | 2025 | |
| Daiichi Sankyo INC. | $22.89 | 2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $19.74 | 2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $17.93 | 2024 | |
| Organon LLC | $16.76 | 2025 | Hadlima, Renflexis |
| Pfizer INC. | $14.96 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.